The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response
Abstract
BACKGROUND AND AIMS: Hepatorenal syndrome (HRS) is characterized by functional renal failure in end-stage liver disease. Terlipressin is the drug of choice for treating type 1 HRS (HRS-1). It is expensive and often not readily available. We, in an open label, randomized, pilot trial, compared the efficacy of terlipressin and noradrenaline on the renal functions and clinical outcome of patients with HRS-1 and also sought predictors of response. PATIENTS AND Forty consecutive patients with HRS-1 were randomized to receive noradrenaline 0.5-3.0 mg/h and METHODS: albumin (group A, N = 20) or terlipressin 0.5-2 mg, 6 hourly and albumin (group B, N = 20), until reversal of HRS (primary end point) or completion of 15 days of therapy (secondary end point). Systemic and renal parameters were monitored. Baseline parameters and delta creatinine at day 4 (DCD4) were used to predict response. RESULTS: The two groups were comparable at baseline. At similar time points, 10 (50%) patients in each group achieved primary end points. Patients in both groups had a significant (P < 0.05) decrease in serum creatinine from baseline (group A day 4 2.4 +/- 1.2 mg/dL, day 8 1.6 +/- 1.2 mg/dL, and day 15 1.0 +/- 0.4 mg/dL; group B day 4 2.5 +/- 1.5 mg/dL, day 8 1.8 +/- 0.9 mg/dL, and day 15 1.2 +/- 0.5 mg/dL) and progressive increase in creatinine clearance (group A day 4 26.5 +/- 12.8 mL/min and day 15 59.8 +/- 14.2 mL/min; group B day 4 31.4 +/- 21.4 mL/min and day 15 54.9 +/- 27.5 mL/min, P < 0.05). Median baseline plasma renin activity was reduced from 38.0 and 42.0 ng/mL/h to 3.0 and 8.0 ng/mL/h (P= 0.08) in groups A and B, respectively. Mean arterial BP and urine output significantly increased in both groups with therapy. Eleven (55%) patients in group A (10 responders) and an equal number in group B (8 responders) survived until day 15 (P= 0.798). Reversible cardiac ischemia was seen in one patient in each group. Noradrenaline therapy was significantly less expensive than terlipressin. On univariate analysis, the following baseline parameters predicted response to therapy: lower grade of encephalopathy, lower MELD score, higher creatinine clearance, higher mean arterial pressure (MAP), and lower plasma renin activity. However, on multivariate analysis only baseline creatinine clearance, MAP, and plasma renin activity were independent predictors of response. At day 4 of therapy, DCD4 was computed and a value of 0.15 mg/dL/day or more accurately predicted response. The sensitivity, specificity, positive predictive value, and negative predictive value for DCD4 0.15 mg/dL/day for predicting response to therapy were 90%, 75%, 78%, and 88%, respectively. CONCLUSIONS: Noradrenaline may be an effective and safe alternative to terlipressin in improving renal functions. Various baseline parameters and DCD4 can be used to predict response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis†
Arroyo, V, Ginès, P., Gerbes, A. L., Dudley, F. J., Gentilini, P., Laffi, G., Reynolds, T. B., Ring-Larsen, H., & Schölmerich, J. (1996) · Hepatology · doi:10.1002/hep.510230122 · Cited by 1,703
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
Ginès, A., Escorsell, A., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90031-7 · Cited by 891
Mitzner, S. R., Stange, J., Klammt, S., Risler, T., Erley, C. M., Bader, B. D., Berger, E. D., Lauchart, W., Peszynski, P., Freytag, J., et al. (2000) · Liver Transplantation · doi:10.1002/lt.500060326 · Cited by 717
Oxford textbook of clinical hepatology
(2000) · Digestive and Liver Disease · doi:10.1016/s1590-8658(00)80409-0 · Cited by 697
Sanyal, A. J., Boyer, T., Garcia–Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., Blei, A., Gülberg, V., Sigal, S., & Teuber, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.014 · Cited by 663
Ortega, R. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00101-5 · Cited by 602
Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide
Angeli, P., Volpin, R., Gerunda, G., Craighero, R., Roner, P., Merenda, R., Amodio, P., Sticca, A., Caregaro, L., Maffei-Faccioli, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290629 · Cited by 564
Ginès, P., Guevara, M., Arroyo, V., & Rodés, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14903-3 · Cited by 517
Hyponatremia in cirrhosis: Results of a patient population survey
Angeli, P., Wong, F., Watson, H., & Ginès, P. (2006) · Hepatology · doi:10.1002/hep.21412 · Cited by 437
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome
Uriz, J., Ginès, P., Cárdenas, A., Sort, P., Jiménez, W., Salmerón, J. M., Bataller, R., Mas, A., Navasa, M., Arroyo, V., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80158-0 · Cited by 399
Cited by
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
Acute kidney injury in cirrhosis
Garcia-Tsao, G., Parikh, C. R., & Viola, A. (2008) · Hepatology · doi:10.1002/hep.22605 · Cited by 662
Human serum albumin, systemic inflammation, and cirrhosis
Arroyo, V., García-Martinez, R., & Salvatella, X. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.012 · Cited by 560
Angeli, P., Garcia-Tsao, G., Nadim, M. K., & Parikh, C. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.002 · Cited by 432
Cavallin, M., Kamath, P. S., Merli, M., Fasolato, S., Toniutto, P., Salerno, F., Bernardi, M., Romanelli, R. G., Colletta, C., Salinas, F., et al. (2015) · Hepatology · doi:10.1002/hep.27709 · Cited by 359
Metadata
- Authors
- Sharma, P., Kumar, A., Shrama, B. C., & Sarin, S. K.
- Venue
- The American Journal of Gastroenterology
- Published
- 2008-07
- Volume
- 103
- Issue
- 7
- Pages
- 1689-1697
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2045620941
- Cited by
- 281
- References
- 16
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response. https://app.cochat.ai/papers/10.1111/j.1572-0241.2008.01828.x
- The paper
- Sharma, P., Kumar, A., Shrama, B. C., & Sarin, S. K. (2008). An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2008.01828.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.